ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Disease Activity"

  • Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting

    The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients

    Mark Berman1, Daphna Paran1, Yonatan Wolman1 and Ori Elkayam2, 1Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
  • Abstract Number: 2991 • 2016 ACR/ARHP Annual Meeting

    A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population

    Michelle Petri1, Kenneth C. Kalunian2, Murray Urowitz3, David A. Isenberg4, Richard Furie5, MaryAnn Morgan-Cox6, Maria Silk7, Ernst R. Dow8, Richard Higgs7, Steven Watts7 and Matthew D Linnik9, 1Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, 2Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, 3Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 4Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 5North Shore University Hospital, Great Neck, NY, 6Eli Lilly and Company, Indianapolis, IN, 7Eli Lilly, Indianapolis, IN, 8Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 9Immunology, Lilly Biotechnology Center, San Diego, CA

    Background/Purpose: Registration trials for SLE therapeutics require large numbers of patients with active disease, which in turn necessitates the trials be multinational with many participating…
  • Abstract Number: 499 • 2016 ACR/ARHP Annual Meeting

    High Levels of Mir-451a Differentiate Patients at Risk of Developing RA from Healthy Controls

    Klára Prajzlerová1, Veronika Hrušková2, Petra Hánová1, Heřman F Mann1, Karel Pavelka1, Jiří Vencovský3, Ladislav Šenolt1 and Mária Filková1, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, Faculty of Science, Charles University in Prague, Prague, Czech Republic, 3Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic

    Background/Purpose:  Individuals with clinically suspect arthralgia (CSA) with positivity of antibodies to citrullinated protein antigens (ACPA) have articular symptoms without clinical signs of arthritis. CSA…
  • Abstract Number: 704 • 2016 ACR/ARHP Annual Meeting

    Does Change in Disease Activity over One Year Result in Change in Health-Related Quality of Life in Early Axial Spondyloarthritis Patients?

    Miranda van Lunteren1, Zineb Ez-Zaitouni1, Pauline Bakker1, Hanne Dagfinrud2, Robert Landewé3, Maikel van Oosterhout4, Roberta Ramonda5, Floris van Gaalen1 and Désirée van der Heijde1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 3Rheumatology, Academic Medical Center, Amsterdam, Netherlands, 4Rheumatology, Groene Hart Ziekenhuis, Gouda, Netherlands, 5Rheumatology Unit, University of Padova, Padova, Italy

    Background/Purpose: In axial Spondyloarthritis (axSpA), treatment is targeted at reducing disease activity  with the aim of improving the health-related quality of life (HRQoL). Therefore, it…
  • Abstract Number: 1055 • 2016 ACR/ARHP Annual Meeting

    Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences

    Nanna Maria Hammer1, Julie Midtgaard2, Merete Lund Hetland3,4, Niels Steen Krogh5 and Bente Appel Esbensen1,6, 1Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, The DANBIO registry and Copenhagen Center for Arthritis Research, Glostrup, Denmark, 2Section of Social Medicine, University of Copenhagen, Copenhagen, Denmark, Department of Public Health, Copenhagen, Denmark, 3Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, 4Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 5Zitelab, Frederiksberg, Denmark, 6Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen, Denmark, Copenhagen, Denmark

    Background/Purpose: While physical activity (PA) has been recommended as a part of the non-pharmacological management of inflammatory arthritis (IA), previous research within this area has…
  • Abstract Number: 1437 • 2016 ACR/ARHP Annual Meeting

    Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis

    Aranzazu Mediero1, Tuere Wilder2, Bhama Ramkhelawon3, Kathryn Moore3 and Bruce Cronstein4, 1Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, 2Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, 3Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, 4Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY

    Background/Purpose:  Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of joints. Netrin-1, a laminin-like matrix protein that acts as a…
  • Abstract Number: 1698 • 2016 ACR/ARHP Annual Meeting

    Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis

    Ari Polachek1, Roa'a Al Johani2, Suzanne Li1, Vinod Chandran1 and Dafna D Gladman3, 1Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: Psoriatic arthritis (PsA) often develops between the 3rd to 5th decades of life. However, little is known about PsA activity and prognosis among patients…
  • Abstract Number: 2012 • 2016 ACR/ARHP Annual Meeting

    Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus

    E. Morand1, A. Berglind2, T. Sheytanova2, R. Tummala3 and G. Illei3, 1Monash University, Melbourne, Australia, 2AstraZeneca, Mölndal, Sweden, 3MedImmune, Gaithersburg, MD

    Background/Purpose: Preliminary validation of a Lupus Low Disease Activity State (LLDAS) definition has demonstrated that LLDAS attainment is associated with reduced damage accrual in patients…
  • Abstract Number: 2501 • 2016 ACR/ARHP Annual Meeting

    Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort

    Ruediger Mueller1, Katja Heinimann2, Rafael Sauter3, Hendrik Schulze-Koops4, Tuulikki Sokka-Isler5, Michael Schiff6 and Johannes von Kempis7, 1Rheumatology, MD, St. Gallen, Switzerland, 2Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland, 3Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland, 4Division for Rheumatology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, 5Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, 6Rheumatology, University of Colorado, Denver, CO, 7Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease leading to joint destructions, if untreated. Treatment with biologic DMARDs has shown to favourably influence disease…
  • Abstract Number: 2768 • 2016 ACR/ARHP Annual Meeting

    Prevalence of Obesity in Patients with Psoriatic Arthritis and Its Impact on the Severity of the Disease

    Cecilia Zaffarana1, Josefina Gallino Yanzi2, Osvaldo Luis Cerda3, Margarita Landi4, Emilce Schneeberger1 and Gustavo Citera1, 1Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 3IREP, CABA, Argentina, 4Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina

    Background/Purpose:  Epidemiological studies have found a high prevalence of obesity in patients with Psoriatic Arthritis (PsA). It was described the association between obesity and severity…
  • Abstract Number: 3016 • 2016 ACR/ARHP Annual Meeting

    Validity of a 2-Component Disease Activity Score for Accurate Assessment of Synovitis in Rheumatoid Arthritis

    Elizabeth M.A. Hensor1,2, Paul McKeigue3, Philip G. Conaghan1,2, Maya H. Buch1,2, Jennifer H. Barrett2,4, Jackie L. Nam1,2, Marco Colombo5, Athina Spiliopoulou5,6, Felix Agakov6, Stephen Kelly7, Myles J. Lewis7, Costantino Pitzalis7, Paul Emery1,2, Ann W. Morgan1,2 and IACON Consortium & PEAC Consortium, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2NIHR-Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 3Medical School, Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom, 4School of Medicine, University of Leeds, Leeds, United Kingdom, 5Centre for Population Health Sciences, University of Edinburgh, Edinburgh, United Kingdom, 6Pharmatics Limited, Edinburgh, Edinburgh, United Kingdom, 7Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom

    Background/Purpose: The original Disease Activity Score (DAS) was derived from clinicians’ therapeutic decisions1, which may have been influenced by patient-subjective factors such as general health…
  • Abstract Number: 16 • 2016 ACR/ARHP Annual Meeting

    Differences Between Patient and Physician Global Assessment on Rheumatoid Arthritis Disease Activity Status in High and Lower Income  Countries Contribute to Inequity

    SA Bergstra1, R van den Berg1, A Chopra2, JAP da Silva3, D Vega-Morales4, N Govind5, TWJ Huizinga6 and RBM Landewé7,8, 1Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, 2Department of Rheumatology, Center for Rheumatic Diseases, Pune, India, Pune, India, 3Department of Rheumatology, SRHUC, Coimbra, Portugal, Coimbra, Portugal, 4Universidad Autónoma de Nuevo Léon, Monterrey, Mexico, Monterrey, Mexico, 5Department of Rheumatology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa, 6Leiden University Medical Centre, Leiden, Netherlands, 7Amsterdam Rheumatology & Immunology Center, Netherlands, Amsterdam, Netherlands, 8Zuyderland Medical Center, Heerlen, Netherlands, Heerlen, Netherlands

    Background/Purpose: Rheumatoid arthritis (RA) patients score their global disease activity (ptGD) on average higher than physicians (phGD). This difference can vary between countries with high…
  • Abstract Number: 510 • 2016 ACR/ARHP Annual Meeting

    C-Reactive Protein and Disease Activity in Rheumatoid Arthritis: Impact of Obesity and Adiposity

    Michael D. George1, Jon T. Giles2, Patricia P. Katz3, Said Ibrahim4, Grant W. Cannon5, Bryant R. England6, Liron Caplan7, Brian Sauer8, Kaleb Michaud9, Ted R Mikuls10 and Joshua F. Baker1, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, Columbia University Medical Center, NY, NY, 3Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 4Medicine, University of Pennsylvania, Philadelphia, PA, 5Salt Lake City VA Medical Center and University of Utah Division of Rheumatology, Salt Lake City, UT, 6Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 7Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, 8IDEAS Center and Division of Epidemiology, HSR&D SLC VA Medical Center and University of Utah, Salt Lake City, UT, 9University of Nebraska Medical Center, Omaha, NE, 10Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: C-reactive protein (CRP) is used to assess disease activity in rheumatoid arthritis (RA), and previous work suggests that adiposity also impacts CRP levels. This…
  • Abstract Number: 722 • 2016 ACR/ARHP Annual Meeting

    Impact of Aerobic Fitness on Axial Spondyloarthritis Activity: Systematic Review and Meta-Analysis of Controlled Studies

    Frank Verhoeven1, Xavier Guillot2, Clément Prati3, Nicolas Tordi4, Céline Demougeot1 and Daniel Wendling5, 1EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, 2EA 4267 FDE, FHU INCREASE, Université de Bourgogne FrancheComté, Besançon, France, 3FDE EA4267, FHU INCREASE, Bourgogne Franche-Comté University, Besançon, France, 4EA 4267 FDE, FHU INCREASE,, Bourgogne Franche-Comté University, Besançon, France, 5Service de Rhumatologie, CHU Jean Minjoz, Besancon, France

    Background/Purpose: The current ASAS recommendations for the management of the ankylosing spondylitis suggest, beside pharmacological therapy, a significant part of physical therapy with supervised exercises.…
  • Abstract Number: 1158 • 2016 ACR/ARHP Annual Meeting

    Effects of an Educational Program Using Treat to Target Strategy in Korean Patients with  Rheumatoid Arthritis

    SeungIn Paek1, Seo Hwa Kim2, Haneul Kim3, Min Kyung Chung4, Jennifer Lee5, Seung-Ki Kwok6, Ji Hyeon Ju7, Sung-Hwan Park7 and Kyeong Yae Sohng8, 1Center for Rheumatic Diseases, Seoul ST Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, 3Division of Rheumatology,, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Republic of Korea, Seoul, Korea, The Republic of, 4Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 6[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 7Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 8College of Nursing, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: The purpose of this study was to investigate the effects of an educational program using T2T (Treat RA to Target, T2T) strategy on Korean…
  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 102
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology